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Background: Using echocardiographic surveillance, many patients are diagnosed with
bicuspid aortic valve (BAV) without significant valve dysfunction. Limited data are available
regarding the progression and outcomes of non-dysfunctional BAV.
Methods and Results: We investigated 1,307 BAV patients (984 male, mean age
56 years) diagnosed from Jan 2003 through Dec 2018 in a single tertiary center.
Seven hundred sixty-one patients underwent follow-up echocardiography at ≥1 year
post-diagnosis. Non-dysfunctional BAV was defined as BAV without moderate aortic
stenosis (AS) or aortic regurgitation (AR). The presence of aortopathy was defined
as an ascending aorta diameter >37mm. Progression to significant BAV dysfunction,
progression to severe aortopathy (ascending aorta diameter ≥45mm), and incidence
of valve or aorta operation were analyzed. One hundred eighty-seven (25%) patients
showed non-dysfunctional BAV. Among them, 104 (56%) had mild AS or AR, and 81
(43%) had aortopathy at indexed echocardiography. At 6.0 ± 3.8 years post-diagnosis,
56 (29%) progressed to dysfunctional BAV, 28 (15%) progressed to severe aortopathy, 22
(12%) underwent valve operation, and 19 (10%) experienced aorta operation. Eighty-nine
percent of patients with normal BAV function and 61% of patients with mild AS or AR
maintained non-dysfunctional BAV. More patients with aortopathy progressed to severe
aortopathy (35 vs. 0% without aortopathy, p <0.001), with a higher incidence of aorta
operation (21 vs. 2%, p < 0.001).
Conclusions: In patients with non-dysfunctional BAV, initial BAV function and degree of
aorta dilatation might be important for progression and outcomes. Patients without any
dysfunction or aortopathy tend to maintain good structure and function for 6 years.
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INTRODUCTION
Bicuspid aortic valve (BAV) is known as the most common
congenital heart valve disease. Patients with BAV exhibit
significant heterogeneity in various clinical aspects, including the
type and degree of valve dysfunction or aortopathy (1–3). As
echocardiographic surveillance has recently been carried out in
the general population, the diagnosis of non-dysfunctional BAV,
in which BAV has no significant aortic stenosis (AS) or aortic
regurgitation (AR), is increasing.
It is well-established that patients with clinically significant
AS or AR incur serious outcome consequences, whether
they have bicuspid or tricuspid valves (4, 5). However,
limited data are available regarding patients with normally
functioning or minimally dysfunctional BAV at initial
diagnosis (6, 7).
Our objective was to determine the incidence of aortopathy
at initial diagnosis and characterize aortic complications
among patients with non-dysfunctional BAV compared with
dysfunctional BAV. We also used a large Korean BAV registry to
assess the progression of valvular dysfunction and aortopathy in
patients with non-dysfunctional BAV.
METHODS
Study Population
We retrospectively reviewed the echocardiographic database and
medical records of patients with BAVs diagnosed from January
2003 to December 2018 at Severance Cardiovascular Hospital
(Yonsei University College of Medicine, Seoul, South Korea).
During this period, 1,307 patients with BAVs were identified
and included in our BAV registry. Among them, 761 patients
had undergone follow-up echocardiography at a minimum of 1
year post-diagnosis.
Significant AS and significant AR were detected via
transthoracic echocardiograms; significant AS was defined
as at least moderate AS, and significant AR was defined
as at least moderate AR, using the guidelines in place
(8, 9). Non-dysfunctional BAV was defined as BAV without
significant AS or AR. Presence of aortopathy was defined
as an ascending aorta (AA) diameter >37mm (10, 11). We
excluded 574 patients with significant AS or AR at the indexed
echocardiogram in this study. Among 574 patients with
dysfunctional BAVs, 354 showed severe AS or severe AR.
During the mean follow-up of 5.9 years, 409 (71%) patients
underwent operations (281 isolated BAV operation, 122 both
BAV and aorta surgery and six isolated aorta surgery). One
hundred eighty-seven non-dysfunctional BAV patients were
classified according to valve function and aortopathy. For
valve function, the patients were divided into the normal valve
function group and the mild AS or AR group. In addition,
they were divided into two groups according to presence of
aortopathy (Figure 1).
The Institutional Review Board of Severance Hospital
approved the present study, which was conducted in compliance
with the Declaration of Helsinki.
Echocardiographic Assessments
Standard two-dimensional and Doppler measurements were
performed following the current guidelines (12). A congenital
BAV was diagnosed when only two cusps were unequivocally
identified in systole and diastole in the short-axis view, with
a clear “fish mouth” appearance during systole, as previously
described (13). Anatomical types of BAV were identified
according to a classification system suggested by Schaefer and
colleagues (14). Type 1 exhibits congenital fusion of the right and
left coronary cusp. Type 2 has a congenital fusion of the right
and non-coronary cusp. Type 3 exhibits a congenital fusion of
the non-coronary and left coronary cusp. Type 0 has no raphe
and is also called “true type BAV.” The severity of AS or AR was
assessed using an integrated approach (9, 15). All measurements
of the aorta were performed according to recommendations on
the QRS complex of the electrocardiogram (12). The dimensions
of the Valsalva sinuses were measured perpendicularly to the
right and left (or non-) aortic sinuses. The sinotubular junction
was measured where the aortic sinuses met the tubular aorta. The
AA was measured ∼2 cm distal to the sinotubular junction, as
described previously (13). Echocardiographic data were gathered
and analyzed by experienced echocardiographers who were
blinded to each patient’s clinical data.
Statistical Analysis
Continuous variables are expressed as a mean ± standard
deviation. Categorical variables are expressed as a number
(percentage). Comparisons between groups were performed
using standard chi-square tests for categorical variables and
student t-tests for continuous variables. Multiple regression
analysis was performed to determine the association between
clinical and echocardiographic variables at the initial diagnosis
and progression to BAV dysfunction or receiving aortic valve
surgery. Similarly, multiple regression analysis was applied to
find factors associated with the progression to severe aortopathy
or receiving aorta surgery. The variables selected for entry into
the multivariate analysis were those with a p-value <0.1 in
the univariate analysis as well as other important variables. All
statistical analyses were performed using SPSS Statistics, version
23.0 (IBM, Armonk, NY, USA). P-values <0.05 were considered
statistically significant.
RESULTS
Baseline Characteristics According to
Valve Function and Aortopathy
Among 761 BAV patients in the registry, 187 (25%) patients
showed non-dysfunctional BAV. Among these, 104 (56%)
patients had mild AS or AR, and 81 (43%) had aortopathy
at indexed echocardiography. The baseline characteristics of
the subjects according to their baseline aortic valve function
or presence of aortopathy were largely comparable (Table 1).
Patients with aortopathy had a higher mean age and a higher use
rate of beta blockers than those without aortopathy. However,
the distribution of comorbidities, including hypertension, was
similar between comparison groups. The most common BAV
morphology was the type 1 morphology of fusion of the left
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FIGURE 1 | Flow chart of the study.













Age, y 52 ± 13 55 ± 13 51 ± 13 58 ± 11†
Male sex 64 (74.4) 81 (77.9) 82 (74.5) 63 (77.8)
BMI, kg/m2 24.4 ± 3.3 23.8 ± 3.1 23.8 ± 3.0 24.5 ± 3.5






Diastolic BP, mmHg 78.6 ± 11.4 79.0 ± 13.0 78.6 ± 12.3 79.1 ± 12.2
Comorbidities
Hypertension 38 (44.7) 52 (50) 54 (49.1) 36 (44.4)
Diabetes mellitus 23 (27.1) 22 (21.2) 27 (24.5) 18 (22.2)
Chronic kidney disease 4 (4.6) 8 (7.7) 9 (8.2) 3 (3.7)
Dyslipidemia 34 (40.0) 30 (28.8) 36 (32.7) 28 (34.6)
Coronary artery
disease
26 (30.6) 23 (22.1) 28 (25.5) 21 (25.9)
Medications
RAAS blocker 27 (33.3) 32 (30.8) 29 (26.4) 30 (37.0)
Beta blocker 20 (24.7) 21 (20.2) 17 (15.5) 24 (29.6)†
Calcium channel
blocker
19 (23.5) 23 (22.1) 27 (24.5) 15 (18.5)
Diuretics 10 (13.3) 15 (14.4) 31 (28.2) 13 (16.0)
Statin 25 (30.9) 26 (25.0) 12 (10.9) 20 (24.7)
Data are shown as Mean ± SD or n (%).
P < 0.05* compared with the normal function group, †compared with the group
without aortopathy.
AS, aortic stenosis; AR, aortic regurgitation; BP, blood pressure; RAAS, renin angiotensin
aldosterone system.
and right coronary cusps in all groups, and the patients with
aortopathy revealed a higher incidence of type 0 morphology
than those without aortopathy (27.2 vs. 14.2%, p = 0.019)
(Table 2). Patients with aortopathy showed a significantly
larger aorta dimension than the other groups. Also, patients
with aortopathy revealed a lower e’ velocity than those
without aortopathy.
Progression to BAV Dysfunction and
Incidence of Aortic Valve Operation
In the normally functioning BAV group, 87% maintained non-
dysfunctional BAV after follow-up (mean follow-up duration:
5.8 yrs). However, in the group with mild AS or AR, 61%
did not show progression to significant valve dysfunction
(mean follow-up duration; 6.2 yrs) (Figure 2A). The follow-up
echocardiographic characteristics and detailed information for
the operation were presented in Supplementary Tables 1 and 2.
Also, aortic valve operation tended to be more frequent in
the group with mild AS or AR, but this did not meet
statistical significance (12.5 vs. 6.0%, p = 0.068) (Table 3). In
the analysis for progression of valve dysfunction according to
BAV morphology, the ratio of progression maintained with
non-dysfunction was similar regardless of the presence of true
type BAV (75 vs. 72%, p = 0.172) (Figure 3A). However, true
type BAV showed a tendency of a higher incidence of valve
operation than other types (19 vs. 10%, p = 0.112) (Figure 3B).
In multivariate analysis, the presence of mild AS and initial aorta
dimension were independently associated with the progression
to non-dysfunctional BAV or receiving aortic valve operation
(Table 4).
Progression to Severe Aortopathy and
Incidence of Aorta Operation
Patients with BAV were subdivided into two groups according
to the presence of aortopathy. Compared to patients without
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aortopathy, the aortopathy group showed a tendency for faster
progression, but this was not statistically significant (0.42 ±
0.85mm vs. 0.32 ± 0.66mm, p = 0.22) (Table 5). None of














Type 1 48 (57.8) 69 (66.3) 69 (65.1) 48 (59.3)
Type 2 14 (16.9) 17 (16.3) 20 (18.9) 11 (13.6)
Type 3 1 (1.2) 1 (1.0) 2 (1.8) 0 (0)
Type 0 20 (24.1) 17 (16.3) 15 (14.2) 22 (27.2)†
BAV function
Normal 83 (100) 0 (0) * 50 (47.2) 33 (40.7)
Mild AR 0 (0) 51 (49.0)* 31 (29.2) 20 (24.7)
Mild AS 0 (0) 36 (34.6)* 17 (16.0) 19 (23.5)
Mild ASR 0 (0) 17 (16.3)* 8 (7.5) 9 (11.1)
Aorta dimension, mm 39.3 ± 5.8 38.5 ± 5.1 32.4 ± 3.5 44.3 ± 6.3†
Annulus, mm 20.0 ± 3.3 20.8 ± 3.3 19.3 ± 2.6 21.9 ± 3.7†
Sinus of Valsalva, mm 34.3 ± 6.4 34.0 ± 9.7 32.0 ± 5.7 36.8 ± 6.6†
Sinotubular junction, mm 30.1 ± 6.0 30.2 ± 5.1 27.6 ± 3.4 33.6 ± 6.0†
LVEDD, mm 49.7 ± 5.9 50.7 ± 6.1 49.6 ± 5.9 51.2 ± 6.1
LVESD, mm 33.7 ± 5.7 33.8 ± 7.0 33.1 ± 6.4 34.6 ± 6.3
LVEF, % 63.1 ± 9.1 64.5 ± 10.2 65.0 ± 8.9 62.7 ± 10.7
LV mass index, g/m2 92.8 ± 27.0 99.6 ± 28.8 95.9 ± 24.8 99.4 ± 32.4
LA volume index, ml/m2 25.0 ± 10.7 29.1 ± 14.0 28.6 ± 13.9 25.5 ± 10.7
e’ velocity, cm/s 7.1 ± 2.4 6.8 ± 2.4 7.5 ± 2.4 6.2 ± 2.2†
S’ velocity, cm/s 7.1 ± 1.5 7.0 ± 1.5 7.1 ± 1.6 6.9 ± 1.4
E/e’ 10.6 ± 4.9 10.7 ± 4.7 10.5 ± 4.5 11.1 ± 5.2
RVSP, mmHg 24.8 ± 6.2 24.5 ± 5.5 24.7 ± 6.3 24.6 ± 5.1
Data are shown as Mean ± SD or n (%).
P < 0.05 *compared with the normal function group, †compared with the group
without aortopathy.
AS, aortic stenosis; AR, aortic regurgitation; BAV, bicuspid aortic valve; ASR, aortic
stenosis with regurgitation; LVEDD, left ventricular end-diastolic dimension; LVESD, left
ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; LV, left ventricle;
LA, left atrium; e’, early diastolic mitral annular; S’, systolic mitral annular; E/e’, the ratio
of early diastolic mitral inflow and early diastolic mitral annular; RVSP, right ventricular
systolic pressure.
the patients without aortopathy experienced a progression of
>45mm in aorta diameter during follow-up (mean 6.0 years),
whereas 34.6% of patients with aortopathy had an increase
in aorta diameter of >45mm (Figure 2B). Furthermore, 9.9%
of the patients with aortopathy had an increase of >50mm.
Also, in the group with aortopathy, the rate of surgery was
significantly higher (21.0 vs. 1.8% without aortopathy, p < 0.001)
during the follow-up period (mean 6.0 years). The progression
of aortopathy was analyzed according to BAV morphology. The
rate of progression to severe aortopathy or the rate of aorta
operation was higher in true type BAV than in other types of
BAV (Figures 3C,D). However, in multivariate analysis, initial
aorta dimension was the single independent predictor for the
progression to severe aortopathy or receiving aorta operation
(Table 6).
DISCUSSION
The principal findings in the present study are that (1) aortopathy
was quite common in patients with BAV, even in the absence
TABLE 3 | Progression of BAV dysfunction and incidence of aortic valve operation.
Normal function
(n = 83)
Mild AS or AR
(n = 104)
Progression to dysfunctional BAV
Moderate dysfunction 5 (6.0) 24 (23.1)*
Severe dysfunction 1 (1.2) 4 (3.8)
Aortic valve operation, n (%) 5 (6.0) 13 (12.5)
Severe dysfunction at operation 3 (3.6) 5 (4.8)
Non-severe dysfunction at operation 2 (2.4) 8 (5.7)
Coronary artery bypass graft 0 (0) 1 (0.9)
Graft replacement of ascending aorta 2 (2.4) 7 (6.7)
Follow-up duration, years 5.8 ± 3.6 6.2 ± 3.9
Data are shown as Mean ± SD or n (%).
*P < 0.05 compared with the normal function group.
AS, aortic stenosis; AR, aortic regurgitation; BAV, bicuspid aortic valve.
FIGURE 2 | Progression to valve dysfunction (A) and aorta dilatation (B) between groups.
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FIGURE 3 | Progression to valve dysfunction (A), the incidence of valve operation (B), the progression to severe aortopathy (C), and incidence of aorta operation (D)
according to BAV morphology.
of significant valvular dysfunction, (2) the progression of AA
dilatation that met the requirements for aorta operation was
more common in BAV patients with aortopathy at initial
diagnosis than in those without aortopathy, (3) 89% maintained
non-dysfunctional BAV after 6 years of follow-up when BAV
patients were diagnosed with normal valve function. However,
only 61% maintained non-dysfunctional BAV in patients with
mild dysfunction, and (4) the rate of progression to severe
aortopathy or the rate of aorta operation was higher in true type
BAV than in other types of BAV.
The ratio of aortopathy to valvulopathy varies in patients
with BAVs. The results of the present study also allow for the
interpretation that the proportion of aortopathy is significant
in the absence of valvulopathy (16–19). Our findings support
previous studies suggesting that BAV is associated with intrinsic
aortopathy, as well as with valve function-related pathology (16–
19). We found that the association with the initial degree of
BAV aortopathy was important in determining the incidence of
aorta operation. Interestingly, when patients with initial normal
valve function with advanced aortopathy (>45mm, 28 patients)
were followed up for 6.1 years, 14 (50.0%) patients underwent
aorta and valve surgery. Four of the 14 patients underwent
aortic valve replacement and aorta surgery for severe AS or
severe AR, and 10 patients underwent aortic valve replacement
with aorta operation, even though BAV function was normal or
mildly dysfunctional. Thus, the aortopathy predominant patients
with non-dysfunctional BAVs experienced aortopathy-associated
clnical events during about 6 years. Because there was no
adequate information on the natural history of existing BAV,
additional aortic valve replacement was considered. However,
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TABLE 4 | Factors associated with the progression to non-dysfunctional BAV or
receiving aortic valve operation.
R = 0.438 β T P-value
Age −0.075 −0.926 0.356
Male sex −0.077 −1.068 0.287
Hypertension 0.041 0.498 0.619
Diabetes mellitus 0.039 0.493 0.623
Chronic kidney disease −0.004 −0.047 0.962
RAAS blocker use −0.027 −0.328 0.744
Beta blocker use −0.041 −0.515 0.607
Statin use 0.014 0.177 0.860
Presence of mild AR 0.046 0.641 0.523
Presence of mild AS 0.305 4.228 <0.001
True type BAV −0.054 −0.748 0.456
Initial aorta dimension, mm 0.314 3.997 <0.001
RAAS, renin angiotensin aldosterone system; AR, aortic regurgitation; AS, aortic stenosis,
BAV, bicuspid aortic valve.





Progression rate, mm/year 0.32 ± 0.66 0.42 ± 0.85
Initial AA diameter, mm 32.3 ± 3.5 42.0 ± 6.3*
Final AA diameter, mm 34.1 ± 3.6 44.0 ± 5.1*
Progression to severe aortopathy
AA diameter ≥ 45mm 0 28 (34.6)*
AA diameter ≥ 50mm 0 8 (9.9)*
Aorta operation 2 (1.8) 17 (21.0)*
Follow-up duration, years 6.0 ± 3.5 6.1 ± 4.1
Data are shown as Mean ± SD or n (%).
*P < 0.05 compared with the group without aortopathy.
AA, ascending aorta.
according to our study, overall 71% of patients with non-
dysfunctional BAVs maintained non-dysfunctional BAVs at 6
years follow-up. In young female patients of childbearing age,
warfarin would be indicated for a long time in operations
performed with mechanical valves. Therefore, when performing
aorta operation in patients with non-dysfunctional BAVs, the
decision of concomitant aortic valve replacement should bemade
cautiously in considering the individual’s risk and benefits.
In general, degenerative changes in BAV patients occur earlier
than in tricuspid AV patients. Recently, the diagnosis of normally
functioning BAV in patients without valve dysfunction and
aortopathy is increasing. There have been studies on factors
that determine valve dysfunction in BAV patients (20–22) or
progression in BAV patients with significant valvular dysfunction
(4). Previous studies have also examined how these factors affect
left ventricular diastolic function, according to BAV morphology
(13). Moreover, a previous report from the Korean BAV cohort
also demonstrated mid-term clinical outcome in asymptomatic
or mildly symptomatic patients with BAVs including both non-
dysfunctional BAVs and dysfunctional BAVs (23).
TABLE 6 | Factors associated with the progression to severe aortopathy or
receiving aorta operation.
R = 0.782 β T P-value
Age −0.006 −0.114 0.909
Male sex −0.30 −0.606 0.545
Hypertension −0.076 −1.320 0.189
Diabetes mellitus 0.012 0.226 0.821
Chronic kidney disease −0.007 −0.144 0.886
RAAS blocker use −0.065 −1.134 0.258
Beta blocker use 0.078 1.397 0.164
Statin use −0.054 −1.000 0.319
Presence of mild AR −0.064 −1.270 0.206
Presence of mild AS 0.022 0.445 0.657
True type BAV −0.007 −0.140 0.889
Initial aorta dimension, mm 0.749 13.724 <0.001
RAAS, renin angiotensin aldosterone system; AR, aortic regurgitation; AS, aortic stenosis;
BAV, bicuspid aortic valve.
However, there have been few studies on the natural course
of normally functioning BAV patients, and in the real world,
patients may wonder about their prognosis and when to perform
a follow-up echocardiogram. As a result, we expect our research
to serve as a reference. Although the mean follow-up duration
was not long enough (about 6 years), ∼89% of patients with
normal valvular functional BAV at the time of diagnosis had
no surgical treatment during the follow-up period, and 71%
of the patients maintained mild valve dysfunction during the
follow-up period. Even for non-dysfunctional BAV patients, if
the aorta is over 37mm at the time of diagnosis, or if there
is mild BAV dysfunction, if true type BAV, the progression of
aortopathy or BAV dysfunction should be regularly examined
by echocardiography.
Studies of BAV have increased rapidly during recent years. An
international BAV consortium has identified knowledge gaps and
risen to the challenge regarding BAV (24). Also, the American
Association for Thoracic Surgery published consensus guidelines
on BAVs (25). Genetic studies on BAV have been published,
some groups have broadened the scope of transcatheter aortic
valve replacement to focus on BAV (26). However, few natural
history data are based on long-term observations. In particular,
the Olmsted county study is an ideal community-based study,
whereas our BAV registry is affected by several sources of bias
because we included a referral cohort. The patients in the
Olmsted County study were obtained by screening through
auscultation revealed that 27% had aortic valve- or aorta-related
surgery within a 20-year follow-up period (27). Similar to our
registry, Olmsted’s study also constructed a cohort in normal
or mild aortic valve disease patients. In Olmsted study, the
results for detailed follow up-echocardiography were missing,
the rate of surgery was shown. Compared to the olmsted
study, it is noteworthy that the rate of surgery of our study
after mean 6 years follow-up is similar. In comparison, our
study has the advantage of including detailed echocardiographic
follow-up data for valve function and aorta dimensions as well as
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clinical outcomes over 6 years in patients with non-dysfunctional
BAV. The present study provides additional information to
help clinicians predict which patients will progress and worsen
clinical outcomes.
LIMITATIONS
The present study had several limitations. First, this retrospective
study included only Korean BAV subjects from a single tertiary
referral center, which may result in bias. Therefore, multi-center,
prospective studies are needed to evaluate the prevalence of
aortopathy in normal valvular BAV and progression of aortic
valve function in BAV. Since the follow-up period for valve
dysfunction is different for each patient, it is limited in its use for
quantitative evaluation of the progression of valve dysfunction.
However, we believe that this study is a meaningful study
that has reported on the prevalence of aortopathy and valve
progression in a large Korean registry using comprehensive
reviews. Additionally, the median follow-up duration was only
6 years, which is insufficient to analyze the long-term natural
history of early BAV disease. Second, data were lacking regarding
common genetic backgrounds in BAV patients. Third, aortic
diameters were measured based on echocardiographic imaging
alone, because only some BAV subjects underwent computed
tomography or cardiac magnetic resonance imaging.
CONCLUSIONS
In patients with non-dysfunctional BAV, initial BAV function and
degree of aorta dilatationmight be important for progression and
outcomes. Patients without any dysfunction or aortopathy tend
to maintain good structure and function for 6 years.
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